Synthesis and biological evaluation of prodigiosene conjugates of porphyrin, estrone and 4-hydroxytamoxifen.

Hawco CL, Marchal E, Uddin MI, Baker AE, Corkery DP, Dellaire G, Thompson A
Bioorg Med Chem. 2013 21 (19): 5995-6002

PMID: 23958515 · DOI:10.1016/j.bmc.2013.07.042

To generate the first series of prodigiosene conjugates, the tripyrrolic skeleton was appended to estrone, tamoxifen and porphyrin frameworks by way of ester linkers and various hydrocarbon chain lengths. The ability of the conjugates to inhibit various types of cancer cells was evaluated in vitro. The porphyrin conjugates did not exhibit significant activity. The estrone conjugates exhibited modest activity, for the most part. However, significantly greater growth inhibition activity against certain breast, colon, lung, leukemia, melanoma and prostate cell lines was noted. This unusual effect for this first generation model class of compound warrants further investigation and comparison to cases where estrogens are linked to prodigiosenes via connection points that do not feature in estrogen receptor binding. The 4-hydroxytamoxifen conjugates exhibit nanomolar range activity against the MCF-7 breast cancer cell line, paving the way to expand the scope and connectivity of prodigiosene-tamoxifen conjugates.

Copyright © 2013 Elsevier Ltd. All rights reserved.

MeSH Terms (11)

Cell Line, Tumor Cell Proliferation Cell Survival Estrone Humans MCF-7 Cells Molecular Structure Neoplasms Porphyrins Prodigiosin Tamoxifen

Connections (1)

This publication is referenced by other Labnodes entities: